Elan considers selling division

Ireland's Elan is considering selling its development and manufacturing division for around $1.5 billion, a move that would leave the company devoted to its bio-pharmaceuticals business. Report

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.